Emerging at the UK, retatrutide, a new compound , is sparking considerable interest within the medical community regarding its promise for body regulation. This dual GIP and GLP-1 agent agonist seems to offer a substantial improvement over existing therapies, showing positive results in preliminary clinical studies . Researchers believe its particu